Beta Bionics, Inc.

NASDAQ:BBNX

Medical - Equipment & Services

Healthcare
$14.33 +3.18%

+$0.42 today

Market cap
$644.70M
Beta
3.39
P/E (TTM)
-9.1
EPS (TTM)
-$1.50
52W Low $8.80High $32.71

Volume 1.38M

Average 0.99M

BBNX Total Debt

Short-term and long-term borrowings combined.

Beta Bionics, Inc.NASDAQ: BBNX

Total Debt · Q1 FY2026 · quarter ended Mar 2026

Total debt broadly unchanged from a year ago

Total debt stood at $6.91M at the end of Q1 FY2026, down 0.9% from a year earlier and down 5.4% from the prior quarter. Over 3 fiscal years it compounded at +20.9% a year.

Context

  • Total debt amounted to 2.3% of total assets at the end of Q1 FY2026, up 0.2 pp from a year earlier.
  • Total debt increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether total debt keeps falling in the next quarterly balance sheet after a -0.9% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$6.91M-5.4% QoQ
Last fiscal yearDec 2025
$7.3M+0.7% YoY
Year agoMar 2025
$6.97M-0.9% since
Total Debt past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-0.9%——
1 year+0.7%——
3-year CAGR+20.9%——
5-year CAGR——
10-year CAGR——

Total Debt history

USD · from the balance sheet

Latest · FY2025
7.3M USD
Year-over-year change
+0.7%
3-year CAGR
+20.9%

Total Debt vs competitors

How BBNX compares with its peers on the latest reported figures

  • Peers report in different currencies, so total debt is compared through growth and share of total assets rather than absolute size.
  • Its year-over-year change of -0.9% is the 5th highest of 7, against a peer median of +45.1%.
  • Total debt amounts to 2.3% of total assets for BBNX, versus a peer median of 23.6%.
BBNX Competitors
Total Debt for BBNX and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
NVONovo Nordisk A/SJun 2026DKK 140.13B DKK+41.2%+71.9%23.6%
DXCMDexCom, Inc.Jun 2026$1.4B USD-45.8%-13.5%21.7%
PODDInsulet CorporationJun 2026$948.4M USD-33.1%-9.8%30.0%
TNDMTandem Diabetes Care, Inc.Mar 2026$734.74M USD+49.0%+1.9%63.7%
MNKDMannKind CorporationMar 2026$436.67M USD+824.2%+18.0%58.7%
MMEDMiniMed Group, Inc. Common StockJul 2026$59M USD——1.3%
BBNXBeta Bionics, Inc.Mar 2026$6.91M USD-0.9%+20.9%2.3%
ORMPOramed Pharmaceuticals Inc.Mar 2026$761K USD+152.8%-2.6%0.3%
Peer median (excluding BBNX) —+45.1%-0.4%23.6%

Competitors are the stored peer set for BBNX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents27.68M26.57M30.43M31.58M
Short-term Investments070.18M73.14M187.55M
Net Receivables04.45M12M19.89M
Inventory01.25M13.32M21.72M
Other Current Assets250K275K1.05M100K
Total Current Assets28.47M103.62M132.92M267.91M
Property, Plant & Equipment (Net)6.87M6.2M11.42M15.23M
Goodwill0000
Intangible Assets0000
Long-term Investments00045.43M
Tax Assets0000
Other Non-current Assets193K221K5.3M180K
Total Non-current Assets7.06M6.42M16.72M60.84M
Total Assets35.53M110.04M149.65M328.74M
Account Payables430K1.17M2.85M5M
Short-term Debt0000
Tax Payables0000
Deferred Revenue087K939K1.56M
Other Current Liabilities1.32M1.14M10.94M14.59M
Total Current Liabilities8.87M10.61M21.15M30.92M
Long-term Debt0000
Deferred Tax Liabilities0000
Deferred Revenue (Non-current)0255K1.86M3.3M
Other Non-current Liabilities10.5M37.83M44.9M1.55M
Total Non-current Liabilities13.65M40.83M52.48M10.21M
Total Liabilities22.53M51.43M73.63M41.13M
Common Stock1K1K1K4K
Retained Earnings(185.57M)(229.66M)(296.74M)(369.94M)
Accumulated OCI0137K65K403K
Other Stockholders Equity0000
Minority Interest0000
Total Equity13M58.61M76.01M287.61M
Total Debt4.13M4.22M7.26M7.3M
Net Debt(23.54M)(22.34M)(23.18M)(24.27M)

Beta Bionics, Inc.

NASDAQ:BBNX

Intrinsic Alpha fair value

Locked

Current Price

$14.33

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.